227 related articles for article (PubMed ID: 31842112)
21. Smoldering multiple myeloma 40 years later: a story of unintended disease.
Yavorkovsky LL
Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
[No Abstract] [Full Text] [Related]
22. Development of early treatment strategies for high-risk myeloma precursor disease in the future.
Landgren O; Rajkumar SV
Semin Hematol; 2011 Jan; 48(1):66-72. PubMed ID: 21232660
[TBL] [Abstract][Full Text] [Related]
23. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
[TBL] [Abstract][Full Text] [Related]
24. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
25. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
[TBL] [Abstract][Full Text] [Related]
26. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
[TBL] [Abstract][Full Text] [Related]
27. Treatment of high-risk smoldering myeloma.
Korde N
Semin Oncol; 2016 Dec; 43(6):695-696. PubMed ID: 28061988
[TBL] [Abstract][Full Text] [Related]
28. Risk Stratification of Precursors to Multiple Myeloma in 2020.
Chudasama R; Barth P
R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
[TBL] [Abstract][Full Text] [Related]
29. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
[TBL] [Abstract][Full Text] [Related]
30. Smoldering multiple myeloma.
Rajkumar SV; Landgren O; Mateos MV
Blood; 2015 May; 125(20):3069-75. PubMed ID: 25838344
[TBL] [Abstract][Full Text] [Related]
31. Practical approach to the management of smoldering myeloma.
Joseph NS; Lonial S
Curr Opin Oncol; 2020 Nov; 32(6):656-663. PubMed ID: 32890022
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
33. The Role of Early Intervention in High-Risk Smoldering Myeloma.
Joseph NS; Dhodapkar MV; Lonial S
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
[TBL] [Abstract][Full Text] [Related]
34. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M; van de Donk NWCJ; Beksac M; Moreau P; Goldschmidt H; Kuppens S; Bandekar R; Clemens PL; Neff T; Heuck C; Qi M; Hofmeister CC
Leukemia; 2020 Jul; 34(7):1840-1852. PubMed ID: 32024950
[TBL] [Abstract][Full Text] [Related]
35. [Smoldering multiple myeloma].
Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
[TBL] [Abstract][Full Text] [Related]
36. Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey.
Mohyuddin GR; Chakraborty R; Cliff ERS; Derman BA
EClinicalMedicine; 2023 Nov; 65():102272. PubMed ID: 38046471
[TBL] [Abstract][Full Text] [Related]
37. Smoldering multiple myeloma.
Gao M; Yang G; Kong Y; Wu X; Shi J
Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
[TBL] [Abstract][Full Text] [Related]
38. What Is New in the Treatment of Smoldering Multiple Myeloma?
Bolli N; Sgherza N; Curci P; Rizzi R; Strafella V; Delia M; Gagliardi VP; Neri A; Baldini L; Albano F; Musto P
J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33499196
[TBL] [Abstract][Full Text] [Related]
39. Smoldering multiple myeloma - Past, present, and future.
Mann H; Katiyar V; Varga C; Comenzo RL
Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
Muchtar E; Kumar SK; Magen H; Gertz MA
Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]